한글목차

승모판막 질환(MVD) 세계 시장 규모는 2024년 32억 5,000만 달러로 평가되었고, 2024년부터 2030년까지 8.85%의 연평균 복합 성장률(CAGR)로 큰 성장이 예상됩니다.

승모판막폐쇄부전증(MVD) 시장은 광범위한 심혈관 기기 및 치료 분야에서 빠르게 성장하고 있습니다. 승모판막 폐쇄부전증(MR) 및 승모판막 협착증(MS)과 같은 질환은 전 세계적으로 널리 퍼져 있어 시장 개발의 큰 기회를 창출하고 있습니다. 이러한 성장을 가속하는 주요 요인으로는 고령화, 심혈관 질환의 유병률 증가, 의료 기술의 지속적인 발전, 저침습적 치료 옵션에 대한 수요 증가 등이 있습니다.

이 시장은 최소침습 수술에 대한 선호도 증가와 진단 및 치료 분야의 기술 혁신에 힘입어 강력한 성장이 예상됩니다. 환자 예후 개선, 치료 접근성 확대, 첨단 기술 통합에 중점을 두면서 MVD 시장은 견조한 성장이 예상됩니다. 특히 고령화 사회에서 승모판막 질환에 대한 인식이 높아짐에 따라 효과적이고 접근하기 쉬운 치료 옵션에 대한 수요도 증가하고 있으며, 이는 시장 성장에 더욱 기여하고 있습니다.

주요 시장 성장 촉진요인

승모판막 질환(MVD) 유병률 증가

주요 시장 이슈

높은 치료비

주요 시장 동향

최소침습 수술의 부상

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장의 승모판막 질환 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 치료 유형별(수복, 치환, 심장재동기 요법, 치료제)
  • 적응증별(협착, 탈출, 역류)
  • 최종사용자별(병원, 외래수술센터(ASC), 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 승모판막 질환 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 캐나다
  • 멕시코

제7장 유럽의 승모판막 질환 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 영국
  • 이탈리아
  • 프랑스
  • 스페인

제8장 아시아태평양의 승모판막 질환 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 인도
  • 일본
  • 한국
  • 호주

제9장 남미의 승모판막 질환 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 승모판막 질환 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병(M&A)

제13장 세계의 승모판막 질환 시장 : SWOT 분석

제14장 Porter의 Five Forces 분석

제15장 경쟁 구도

• Corcym UK Limited
• Abbott Laboratories Inc
• Zydus Lifesciences Limited
• Medtronic plc
• Edwards Lifesciences Corporation
• Affluent Medical SA
• ShockWave Medical, Inc.
• Valcare Medical
• Pfizer Inc
• Teva Pharmaceutical Industries Ltd.

제16장 전략적 제안

제17장 리서치사에 대해 & 면책사항

영문목차

The global Mitral Valve Disease (MVD) market was valued at USD 3.25 billion in 2024 and is projected to experience significant growth, with a compound annual growth rate (CAGR) of 8.85% from 2024 to 2030. The MVD market is rapidly expanding within the broader cardiovascular devices and treatments sector. Conditions like mitral valve regurgitation (MR) and mitral valve stenosis (MS) are prevalent worldwide, creating substantial opportunities for market development. Key drivers of this growth include an aging population, the increasing prevalence of cardiovascular diseases, continuous advancements in medical technologies, and rising demand for minimally invasive treatment options.

This market is expected to experience strong growth, fueled by innovations in diagnostics and treatments, alongside a growing preference for minimally invasive procedures. With a focus on improving patient outcomes, expanding access to care, and integrating cutting-edge technologies, the MVD market is poised for robust expansion. As awareness of mitral valve disease increases, particularly in aging populations, the demand for effective and accessible treatment options is also on the rise, further contributing to market growth.

Key Market Drivers

Growing Prevalence of Mitral Valve Disease (MVD)

The rising prevalence of mitral valve disease (MVD) is a primary factor driving the growth of the global MVD market. As MVD becomes more common worldwide, the demand for diagnostic services, treatment options, and healthcare infrastructure tailored to this condition is escalating. Alongside aging, modern lifestyle factors such as obesity, hypertension, diabetes, and smoking are contributing to the higher incidence of MVD. These lifestyle-related conditions are increasingly prevalent, particularly in emerging economies, driving the number of MVD cases.

Obesity is a major global concern, with one in eight individuals living with obesity as of 2022. The prevalence of adult obesity has more than doubled since 1990, with over 890 million adults affected. Hypertension is also widespread, with 1.28 billion adults aged 30 to 79 suffering from the condition, particularly in low- and middle-income countries. This growing incidence of hypertension and obesity directly impacts the prevalence of MVD, placing additional demand on healthcare systems.

The global increase in life expectancy further contributes to the rising incidence of MVD. As people live longer, the likelihood of developing MVD increases, resulting in a larger patient population requiring long-term treatment and management. The global life expectancy is projected to rise from 73.6 years in 2022 to 78.1 years by 2050, which presents both challenges and opportunities for healthcare businesses in addressing the needs of an aging population.

Additionally, as cardiovascular diseases (CVDs) continue to be the leading cause of global mortality, MVD is emerging as a significant contributor to heart failure and related complications. This escalating burden highlights the urgent need for effective diagnostic, treatment, and management solutions for MVD, thus driving market demand.

Key Market Challenges

High Treatment Costs

A major challenge for the growth of the Global Mitral Valve Disease Market is the high cost associated with diagnosis and treatment. Mitral valve diseases often necessitate complex surgical interventions or the implantation of prosthetic valves, which can be prohibitively expensive. Traditional open-heart surgeries and minimally invasive techniques such as transcatheter mitral valve repair (TMVR) both incur significant costs, including surgeon fees, operating room charges, and the cost of prosthetic devices.

Post-operative care and recovery for MVD patients also contribute to high healthcare costs, which include follow-up appointments, medications, and cardiac rehabilitation. In certain regions, inadequate insurance coverage for MVD treatments further compounds the financial burden, potentially deterring patients from seeking timely medical attention and hindering market growth.

Key Market Trends

Rise of Minimally Invasive Procedures

One of the prominent trends in the Global Mitral Valve Disease Market is the increasing adoption of minimally invasive procedures for diagnosing and treating MVD. Traditional open-heart surgery has long been the standard approach, but advances in medical technology have introduced less invasive options, such as transcatheter mitral valve repair (TMVR) and transcatheter mitral valve replacement (TMVR).

Minimally invasive procedures offer several advantages, including smaller incisions, reduced pain, shorter hospital stays, and faster recovery times. These benefits are driving greater patient demand for minimally invasive options, particularly among high-risk or elderly patients who may not be candidates for open-heart surgery. As healthcare professionals gain expertise in performing these procedures, their adoption is expected to continue to rise.

Key Market Players

• Corcym UK Limited
• Abbott Laboratories Inc.
• Zydus Lifesciences Limited
• Medtronic plc
• Edwards Lifesciences Corporation
• Affluent Medical SA
• ShockWave Medical, Inc.
• Valcare Medical
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.

Report Scope:

This report segments the Global Mitral Valve Disease Market into the following categories, along with the industry trends:

Mitral Valve Disease Market by Treatment Type:

• Repair
• Replacement
• Cardiac Resynchronization Therapy
• Therapeutics

Mitral Valve Disease Market by Indication:

• Stenosis
• Prolapse
• Regurgitation

Mitral Valve Disease Market by End-User:

• Hospitals
• Ambulatory Surgical Centers
• Others

Mitral Valve Disease Market by Region:

• North America: United States, Canada, Mexico
• Europe: France, United Kingdom, Italy, Germany, Spain
• Asia-Pacific: China, India, Japan, Australia, South Korea
• South America: Brazil, Argentina, Colombia
• Middle East & Africa: South Africa, Saudi Arabia, UAE

Competitive Landscape

This section provides a detailed analysis of major companies in the Global Mitral Valve Disease Market.

Available Customizations:

TechSci Research offers tailored customizations to the Global Mitral Valve Disease market report, providing specific data and insights according to a company's needs. Customization options include:

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Mitral Valve Disease Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment Type (Repair, Replacement, Cardiac Resynchronization Therapy, Therapeutics)
  • 5.2.2. By Indication (Stenosis, Prolapse, Regurgitation)
  • 5.2.3. By End-User (Hospitals, Ambulatory Surgical Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Mitral Valve Disease Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment Type
  • 6.2.2. By Indication
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Mitral Valve Disease Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment Type
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By End-User
  • 6.3.2. Canada Mitral Valve Disease Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment Type
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By End-User
  • 6.3.3. Mexico Mitral Valve Disease Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment Type
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By End-User

7. Europe Mitral Valve Disease Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type
  • 7.2.2. By Indication
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Mitral Valve Disease Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment Type
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By End-User
  • 7.3.2. United Kingdom Mitral Valve Disease Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment Type
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By End-User
  • 7.3.3. Italy Mitral Valve Disease Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment Type
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By End-User
  • 7.3.4. France Mitral Valve Disease Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment Type
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By End-User
  • 7.3.5. Spain Mitral Valve Disease Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment Type
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By End-User

8. Asia-Pacific Mitral Valve Disease Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By Indication
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Mitral Valve Disease Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By End-User
  • 8.3.2. India Mitral Valve Disease Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By End-User
  • 8.3.3. Japan Mitral Valve Disease Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By End-User
  • 8.3.4. South Korea Mitral Valve Disease Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment Type
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By End-User
  • 8.3.5. Australia Mitral Valve Disease Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment Type
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By End-User

9. South America Mitral Valve Disease Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By Indication
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Mitral Valve Disease Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By End-User
  • 9.3.2. Argentina Mitral Valve Disease Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By End-User
  • 9.3.3. Colombia Mitral Valve Disease Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By End-User

10. Middle East and Africa Mitral Valve Disease Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment Type
  • 10.2.2. By Indication
  • 10.2.3. By End-User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Mitral Valve Disease Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment Type
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By End-User
  • 10.3.2. Saudi Arabia Mitral Valve Disease Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment Type
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By End-User
  • 10.3.3. UAE Mitral Valve Disease Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment Type
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Mitral Valve Disease Market: SWOT Analysis

14. Porter's Five Forces Analysis

15. Competitive Landscape

• 15.1. Corcym UK Limited
  • 15.1.1. Business Overview
  • 15.1.2. Product & Service Offerings
  • 15.1.3. Recent Developments
  • 15.1.4. Financials (If Listed)
  • 15.1.5. Key Personnel
  • 15.1.6. SWOT Analysis
• 15.2. Abbott Laboratories Inc
• 15.3. Zydus Lifesciences Limited
• 15.4. Medtronic plc
• 15.5. Edwards Lifesciences Corporation
• 15.6. Affluent Medical SA
• 15.7. ShockWave Medical, Inc.
• 15.8. Valcare Medical
• 15.9. Pfizer Inc
• 15.10.Teva Pharmaceutical Industries Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer